LTZ Therapeutics Revenue and Competitors

Location

#4558

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • LTZ Therapeutics's estimated annual revenue is currently $2.6M per year.(i)
  • LTZ Therapeutics's estimated revenue per employee is $77,500
  • LTZ Therapeutics's total funding is $27M.

Employee Data

  • LTZ Therapeutics has 33 Employees.(i)
  • LTZ Therapeutics grew their employee count by 38% last year.

LTZ Therapeutics's People

NameTitleEmail/Phone
1
Founder, CEOReveal Email/Phone
2
SVP and Co-founderReveal Email/Phone
3
Co-founder & SVP, Biologics DiscoveryReveal Email/Phone
4
Co-founder & Chief Scientific OfficerReveal Email/Phone
5
VP, Pre-clinical DevelopmentReveal Email/Phone
6
VP Preclinical DevelopmentReveal Email/Phone
7
Associate Director, Biology and Translational SciencesReveal Email/Phone
8
Project Manager and Business DevelopmentReveal Email/Phone
9
HR ManagerReveal Email/Phone
10
Senior ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is LTZ Therapeutics?

LTZ Therapeutics is an immunotherapy-focused biotech company to develop novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need. With main operations in Palo Alto, California and Shenzhen China as well as a team out of Heidelberg Germany, LTZ is dedicated to developing immunotherapies capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science and emerging biology of tumor microenvironment.

keywords:N/A

$27M

Total Funding

33

Number of Employees

$2.6M

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.3M3374%$3.2M
#2
$3.8M33-3%N/A
#3
$4.2M333%N/A
#4
$5.1M33-15%N/A
#5
$7.3M33-20%N/A